The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System.
1 other identifier
interventional
18
1 country
1
Brief Summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential hypertension - during baseline conditions and after activation of the sympathetic nervous system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jan 2007
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
February 20, 2007
CompletedFirst Posted
Study publicly available on registry
February 22, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2008
CompletedMay 9, 2008
May 1, 2008
February 20, 2007
May 5, 2008
Conditions
Outcome Measures
Primary Outcomes (3)
Heart rate
Fractional sodium excretion
Plasma levels of noradrenaline
Secondary Outcomes (5)
Fractional lithium excretion
Glomerular filtration rate
plasma levels of renin, angiotensin II, aldosterone, vasopressin, atrial natriuretic peptide and brain natriuretic peptide
free water clearance
urinary excretion of aquaporin 2
Interventions
Eligibility Criteria
You may qualify if:
- Age 18 - 65 years.
- Body mass index less or equal to 30 kg/m2.
- Women must use oral hormonal anticonceptive drugs, use intrauterine anticonceptive device, be sterilized / hysterectomized or be postmenopausal.
- Arterial hypertension, defined by 24 hour ambulatory blood pressure above 125 mmHg systolic or above 80 mmHg diastolic.
You may not qualify if:
- History of myocardial infarction.
- History of stroke.
- Heart failure.
- Endocrine organ disease.
- Lung disease.
- Clinically significant abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine (under 200 µmol/L will be accepted), P-albumin, p-bilirubin, p-alaninaminotransferase, P-alkaline phosphatase, p-cholesterol and B-glucose.
- Clinically significant abnormal screening of the urine regarding: albumin and glucose (protein excretion below 0.5 g/L will be accepted).
- Renovascular hypertension.
- Malignant disease.
- Alcohol abuse.
- Usage of medical drugs besides antihypertensives or statins.
- Drug abuse.
- Pregnancy or breast feeding.
- Known intolerance or allergic to eprosartan or sodium nitroprusside.
- Blood donation within 1 month of the start of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Medical Research, Holstebro Hospital
Holstebro, 7500, Denmark
Related Publications (1)
Vase H, Lauridsen TG, Graffe CC, Pedersen EB. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension. J Am Soc Hypertens. 2011 Sep-Oct;5(5):385-94. doi: 10.1016/j.jash.2011.03.007. Epub 2011 Jun 2.
PMID: 21640689DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Erling B Pedersen, MD, professor
Department of Medical Research, Holstebro Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 20, 2007
First Posted
February 22, 2007
Study Start
January 1, 2007
Study Completion
January 1, 2008
Last Updated
May 9, 2008
Record last verified: 2008-05